High-concentration hydrogen protects mouse heart against ischemia/reperfusion injury through activation of thePI3K/Akt1 pathway.
Ouyang Chen, Zhiyong Cao, He Li, Zhouheng Ye, Rongjia Zhang, Ning Zhang, Junlong Huang, Ting Zhang, Liping Wang, Ling Han, Wenwu Liu, Xuejun Sun · Scientific reports · 2017
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
High-concentration hydrogen protects mouse heart against ischemia/reperfusion injury through activation of thePI3K/Akt1 pathway. These results are preclinical and suggest molecular hydrogen's therapeutic potential in the condition studied. Further human research is needed to establish clinical effectiveness.
What the Researchers Studied
The study examined c57BL/6 mice.
How Molecular Hydrogen Was Used
In vitro, 75% hydrogen was administered to cardiomyocytes during 4 h of reoxygenation after 3-h hypoxia.
What the Researchers Found
After 45 min of ischemia, HCH (67% H₂ and 33% O₂) was administered to mice during a 90-min reperfusion. In vitro, 75% hydrogen was administered to cardiomyocytes during 4 h of reoxygenation after 3-h hypoxia. The study investigated the role of Akt1 through the cardioprotection of high-concentration hydrogen (HCH).
H₂ Mechanisms / Biological Findings
The source material reviewed did not establish a specific molecular hydrogen mechanism for the reported findings.
Authors’ Conclusion
A distinct authors’ conclusion was not available in the source material reviewed by H2HUBB.